Cargando…
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common retinal vascular diseases responsible for most blindness in the working-age and older population in developed countries. Currently, anti-VEGF agents that block VEGF family ligands, including ranibizumab,...
Autores principales: | Liberski, Sławomir, Wichrowska, Małgorzata, Kocięcki, Jarosław |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409486/ https://www.ncbi.nlm.nih.gov/pubmed/36012690 http://dx.doi.org/10.3390/ijms23169424 |
Ejemplares similares
-
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
por: Ferro Desideri, Lorenzo, et al.
Publicado: (2023) -
Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022) -
Examination of Inner Retinal Layers in Unilateral Wet Age-Related Macular Degeneration Treated with Anti-VEGF, Compared to Fellow Untreated Eyes
por: Wichrowska, Małgorzata, et al.
Publicado: (2022) -
Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023) -
One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B
Publicado: (2023)